Trial Profile
Vaccination with autologous dendritic cells pulsed with allogeneic tumour lysate (MelCancerVac) for the treatment of patients with advanced or metastatic non-small cell lung cancer. A phase II study
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 30 Mar 2012
Price :
$35
*
At a glance
- Drugs Celecoxib (Primary) ; Dendritic-cell-vaccine-Enochian-Biosciences (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- 19 Mar 2012 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Apr 2007 New trial record.